U.S. Markets closed

Aytu BioScience, Inc. (AYTU)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9902-0.0198 (-1.96%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.0100
Open1.0000
Bid1.0000 x 1100
Ask1.0100 x 4000
Day's Range0.9850 - 1.0200
52 Week Range0.3400 - 2.9900
Volume1,432,635
Avg. Volume3,644,695
Market Cap124.604M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.3010
Earnings DateNov 12, 2020 - Nov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.63
  • Benzinga

    Recap: Aytu BioScience Q4 Earnings

    Shares of Aytu BioScience (NASDAQ:AYTU) fell 6.77% after the company reported Q4 results.Quarterly Results Earnings per share rose 98.46% over the past year to ($0.02), which beat the estimate of ($0.03).Revenue of $14,861,000 rose by 766.03% from the same period last year, which beat the estimate of $11,240,000.Looking Ahead Aytu BioScience hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Oct 06, 2020View more earnings on AYTUTime: 04:30 PMET Webcast URL: https://www.webcaster4.com/Webcast/Page/2142/37506Price Action Company's 52-week high was at $2.99Company's 52-week low was at $0.34Price action over last quarter: down 14.42%Company Profile Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Earnings Scheduled For October 6, 2020 * Preview: Aytu BioScience's Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Aytu BioScience Announces Fiscal Q4 2020 Net Revenue of $14.9 Million, an Increase of 82% Sequentially, and 766% Year-Over-Year

    Company's highest revenue quarter to date is more than 2X its entire fiscal 2019 revenueENGLEWOOD, CO / ACCESSWIRE / October 6, 2020 / Aytu BioScience, Inc.

  • Benzinga

    Preview: Aytu BioScience's Earnings

    Aytu BioScience (NASDAQ: AYTU) releases its next round of earnings this Tuesday, October 06. Get the latest predictions in Benzinga's essential guide to the company's Q4 earnings report.Earnings and Revenue Sell-side analysts are expecting Aytu BioScience's loss per share to be near $0.03 on sales of $11.24 million. Aytu BioScience's loss in the same period a year ago was $1.3 per share. Quarterly sales came in at $1.72 million. The analyst consensus estimate would represent a 97.69% increase in the company's earnings per share. In comparison to analyst estimates in the past, here's how the company's reported EPS stacks up:Quarter Q3 2020 Q2 2020 Q1 2019 Q4 2019 EPS Estimate -0.22 -0.24 -0.30 -2.15 EPS Actual -0.15 -0.31 -0.32 -1.30 Revenue Estimate 6.40 M 2.74 M 2.01 M 17.04 M Revenue Actual 8.16 M 3.17 M 1.44 M 1.72 M Stock Performance Over the last 52-week period, shares of Aytu BioScience are up 26.6%.View more earnings on AYTUDon't be surprised to see the stock move on comments made during its conference call. Aytu BioScience is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://www.webcaster4.com/Webcast/Page/2142/37506See more from Benzinga * Options Trades For This Crazy Market: Get Benzinga Options to Follow High-Conviction Trade Ideas * Earnings Scheduled For September 24, 2020 * Aytu BioScience's Earnings Outlook(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.